AVEN 抗体 (N-Term)
(3 references)Quick Overview for AVEN 抗体 (N-Term) (ABIN1881095)
抗原
See all AVEN 抗体适用
宿主
克隆类型
标记
应用范围
克隆位点
-
-
抗原表位
- AA 78-106, N-Term
-
纯化方法
- This antibody is purified through a protein A column, followed by peptide affinity purification.
-
免疫原
- This AVEN antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 78-106 amino acids from the N-terminal region of human AVEN.
-
亚型
- Ig Fraction
-
-
anti-Apoptosis, Caspase Activation Inhibitor (AVEN) (AA 71-170) antibody
AVEN 适用: 人 WB, ELISA 宿主: 小鼠 Monoclonal 2B10 unconjugated
anti-Apoptosis, Caspase Activation Inhibitor (AVEN) (C-Term) antibodyAVEN 适用: 人 WB, ELISA, IF, ICC 宿主: 兔 Polyclonal unconjugated
anti-Apoptosis, Caspase Activation Inhibitor (AVEN) (AA 254-362) antibodyAVEN 适用: 人 WB, ELISA, IHC 宿主: 小鼠 Monoclonal 3G4 unconjugated
anti-Apoptosis, Caspase Activation Inhibitor (AVEN) (C-Term) antibodyAVEN 适用: 人, 猴 WB, IHC, IF, IC 宿主: 兔 Polyclonal unconjugated
anti-Apoptosis, Caspase Activation Inhibitor (AVEN) (C-Term) antibodyAVEN 适用: 人, 猴 WB, ELISA, IHC, IF 宿主: 兔 Polyclonal unconjugated
anti-Apoptosis, Caspase Activation Inhibitor (AVEN) (AA 203-362) antibodyAVEN 适用: 人 WB, IF 宿主: 兔 Polyclonal unconjugated
anti-Apoptosis, Caspase Activation Inhibitor (AVEN) (C-Term) antibodyAVEN 适用: 人, 小鼠, 大鼠 WB, IHC (p), EIA 宿主: 兔 Polyclonal unconjugated
anti-Apoptosis, Caspase Activation Inhibitor (AVEN) (N-Term) antibodyAVEN 适用: 人, 小鼠, 大鼠 WB, IHC (p), EIA 宿主: 兔 Polyclonal unconjugated
-
-
应用备注
- WB: 1:1000
-
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
缓冲液
- Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
-
储存液
- Sodium azide
-
注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
储存条件
- 4 °C,-20 °C
-
有效期
- 6 months
-
-
-
: "Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study." in: Diabetes Care, Vol. 33, Issue 10, pp. 2250-3, (2010) (PubMed).
: "Physiogenomic analysis of statin-treated patients: domain-specific counter effects within the ACACB gene on low-density lipoprotein cholesterol?" in: Pharmacogenomics, Vol. 11, Issue 7, pp. 959-71, (2010) (PubMed).
: "Transcriptome sequencing of malignant pleural mesothelioma tumors." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 105, Issue 9, pp. 3521-6, (2008) (PubMed).
-
: "Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study." in: Diabetes Care, Vol. 33, Issue 10, pp. 2250-3, (2010) (PubMed).
-
-
